Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.47 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.62 |
| ▸ | METAP2 | P50579 | 2/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | NCF1 | P14598 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL672744 | 0.90 | METAP2 (0.63) | KDM4EALOX12METAP2PLAUNCF1 | |
| SCHEMBL30082244 | 0.90 | METAP2 (0.63) | KDM4EALOX12METAP2PLAUNCF1 | |
| SCHEMBL15442576 | 0.88 | METAP2 (0.61) | KDM4EALOX12METAP2PLAUNCF1 | |
| SCHEMBL1496246 | 0.88 | METAP2 (0.61) | KDM4EALOX12METAP2PLAUNCF1 | |
| SCHEMBL8467827 | 0.88 | METAP2 (0.61) | KDM4EALOX12METAP2PLAUNCF1 | |
| SCHEMBL16444064 | 0.88 | METAP2 (0.61) | KDM4EALOX12METAP2PLAUNCF1 | |
| SCHEMBL6540982 | 0.88 | METAP2 (0.61) | KDM4EALOX12METAP2PLAUNCF1 | |
| SCHEMBL413180 | 0.88 | METAP2 (0.61) | KDM4EALOX12METAP2PLAUNCF1 | |
| Ammonia Solution, Strong SCHEMBL3284067 | 0.88 | METAP2 (0.61) | KDM4EALOX12METAP2PLAUNCF1 | |
| SCHEMBL7738434 | 0.88 | METAP2 (0.61) | KDM4EALOX12METAP2PLAUNCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | UNIV CALIFORNIA (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4622471-A1 | BOVINE COLOSTRUM-DERIVED NUTRITIONAL SUPPLEMENTS AND USES THEREOF | University of Maryland, Baltimore (US) | 2025-10-01 | — | — | EP | disclosed |
| WO-2024112738-A1 | BOVINE COLOSTRUM-DERIVED NUTRITIONAL SUPPLEMENTS AND USES THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20230256034-A1 | METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE AND ALLERGIC DISORDERS | THE UNIVERSITY PF CHICAGO (US) | 2023-08-17 | — | — | US | disclosed |
| US-5712164-A | Method for reducing contamination of in vitro cultures of shoot material | WESTVACO CORPORATION (US) | 1998-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | CYP27A1, LIPC, CYP46A1 | CHRM1 4678/4885ADRA1A 2259/4885KDM4E 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.